@MFernandez-Chas
discovered that HCPCS codes have the wrong mapping
The HCPCS codes for cancer therapeutic drugs Kymriah (Q2040, Q2042) and Yescarta (Q2041) seem to be mapped to non-cancer drugs. Here is the current mapping with the corresponding description:
HCPCS Q2040
OMOP Concept ID: 35605867
OMOP Concept Name: Botulinum Toxin Type A Injection
HCPCS Q2042
OMOP Concept ID: 36249937
OMOP Concept Name: 17-alpha-Hydroxyprogesterone Injection
HCPCS Q2041
OMOP Concept ID: 41085967
OMOP Concept Name: von Willebrand factor 1 UNT Injectable Solution
The thing is that these codes changed their meaning over time,
for example:
Q2042 was “Injection, hydroxyprogesterone caproate, 1 mg” till 2017-11-05,
but beginning from 2019-01-01 it becomes “Tisagenlecleucel, up to 600 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose”
So, we can’t just change the mapping, because if the Q2042 concept exists in a patient data before 2017, the mapping to “hydroxyprogesterone caproate” is correct.
@Christian_Reich, @aostropolets,
Thoughts?